Tower Research Capital (TRC)’s NanoViricides NNVC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.03K | Sell |
3,642
-3,274
| -47% | -$4.49K | ﹤0.01% | 4315 |
|
|
2026
Q1 | $6.31K | Buy |
6,916
+2,557
| +59% | +$2.68K | ﹤0.01% | 4063 |
|
|
2025
Q4 | $4.93K | Buy |
4,359
+3,536
| +430% | +$4.97K | ﹤0.01% | 4164 |
|
|
2025
Q3 | $1.18K | Buy |
+823
| New | +$1.23K | ﹤0.01% | 4858 |
|
|
2025
Q2 | – | Sell |
-4,663
| Closed | -$5.46K | – | 5474 |
|
|
2025
Q1 | $5.46K | Buy |
4,663
+2,760
| +145% | +$3.5K | ﹤0.01% | 4123 |
|
|
2024
Q4 | $2.72K | Sell |
1,903
-468
| -20% | -$672 | ﹤0.01% | 4788 |
|
|
2024
Q3 | $3.56K | Buy |
2,371
+145
| +7% | +$269 | ﹤0.01% | 4824 |
|
|
2024
Q2 | $3.83K | Buy |
2,226
+1,619
| +267% | +$2.88K | ﹤0.01% | 4851 |
|
|
2024
Q1 | $704 | Buy |
+607
| New | +$696 | ﹤0.01% | 5402 |
|
|
2023
Q2 | – | Sell |
-1,526
| Closed | -$2K | – | 6264 |
|
|
2023
Q1 | $2K | Sell |
1,526
-127
| -8% | -$171 | ﹤0.01% | 5377 |
|
|
2022
Q4 | $2K | Buy |
+1,653
| New | +$2.58K | ﹤0.01% | 5400 |
|
|
2022
Q3 | – | Sell |
-2,251
| Closed | -$4K | – | 6341 |
|
|
2022
Q2 | $4K | Sell |
2,251
-1,698
| -43% | -$3.12K | ﹤0.01% | 5236 |
|
|
2022
Q1 | $8K | Buy |
+3,949
| New | +$9.22K | ﹤0.01% | 4600 |
|
|
2021
Q4 | – | Sell |
-2,767
| Closed | -$13K | – | 6423 |
|
|
2021
Q3 | $13K | Buy |
2,767
+2,622
| +1,808% | +$10.9K | ﹤0.01% | 4093 |
|
|
2021
Q2 | $1K | Sell |
145
-27,886
| -99% | -$113K | ﹤0.01% | 5224 |
|
|
2021
Q1 | $132K | Buy |
28,031
+27,471
| +4,906% | +$124K | ﹤0.01% | 2350 |
|
|
2020
Q4 | $2K | Sell |
560
-4,069
| -88% | -$14.8K | ﹤0.01% | 4901 |
|
|
2020
Q3 | $18K | Buy |
+4,629
| New | +$25.4K | ﹤0.01% | 3899 |
|
|
2018
Q1 | – | Sell |
-128
| Closed | -$2K | – | 3653 |
|
|
2017
Q4 | $2K | Buy |
128
+97
| +313% | +$1.98K | ﹤0.01% | 3227 |
|
|
2017
Q3 | $1K | Sell |
31
-350
| -92% | -$9.4K | ﹤0.01% | 3666 |
|
|
2017
Q2 | $10K | Sell |
381
-250
| -40% | -$6.18K | ﹤0.01% | 1615 |
|
|
2017
Q1 | $14K | Sell |
631
-304
| -33% | -$7.09K | ﹤0.01% | 1549 |
|
|
2016
Q4 | $20K | Buy |
935
+438
| +88% | +$11.7K | ﹤0.01% | 2145 |
|
|
2016
Q3 | $17K | Buy |
497
+161
| +48% | +$5.34K | ﹤0.01% | 1716 |
|
|
2016
Q2 | $11K | Buy |
336
+201
| +149% | +$7.33K | ﹤0.01% | 2738 |
|
|
2016
Q1 | $6K | Buy |
+135
| New | +$5.24K | ﹤0.01% | 2542 |
|
|
2015
Q4 | – | Sell |
-22
| Closed | -$1K | – | 4865 |
|
|
2015
Q3 | $1K | Sell |
22
-6
| -21% | -$159 | ﹤0.01% | 3650 |
|
|
2015
Q2 | $1K | Buy |
28
+4
| +17% | +$152 | ﹤0.01% | 4036 |
|
|
2015
Q1 | $1K | Sell |
24
-65
| -73% | -$3.47K | ﹤0.01% | 4091 |
|
|
2014
Q4 | $5K | Sell |
89
-1,020
| -92% | -$67.5K | ﹤0.01% | 2730 |
|
|
2014
Q3 | $67K | Buy |
1,109
+920
| +487% | +$72.3K | 0.01% | 1294 |
|
|
2014
Q2 | $15K | Buy |
189
+84
| +80% | +$5.96K | ﹤0.01% | 2042 |
|
|
2014
Q1 | $7K | Buy |
+105
| New | +$8.97K | ﹤0.01% | 2980 |
|
Other funds holding NNVC
CCM
MFS
Tower Research Capital (TRC)'s NNVC Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its NanoViricides (NNVC) stake by 47% in Q2 2026, selling an estimated $4.49K and leaving 3,642 shares worth $5.03K. The position accounts for ﹤0.01% of the portfolio, ranked #4315.
Tower Research Capital (TRC) first reported a position in NNVC in Q1 2014 and has held it in 33 quarters since. The position peaked at $132K in Q1 2021. 48 funds tracked by Wall St. Rank hold NNVC as of Q2 2026.
- Tower Research Capital (TRC) held 3,642 shares of NanoViricides worth $5.03K as of Q2 2026.
- Tower Research Capital (TRC) sold 3,274 NanoViricides shares in Q2 2026, an estimated $4.49K.
- NanoViricides made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4315 holding.
- Tower Research Capital (TRC) first reported a position in NanoViricides in Q1 2014 and has held it in 33 quarters since.
- Tower Research Capital (TRC)'s NanoViricides position peaked at $132K in Q1 2021.
- 48 funds tracked by Wall St. Rank held NanoViricides as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.